7b9625284b
- Source: inbox/queue/2026-05-08-glp1-cocaine-use-disorder-phase2-recruiting-2025.md - Domain: health - Claims: 0, Entities: 2 - Enrichments: 1 - Extracted by: pipeline ingest (OpenRouter anthropic/claude-sonnet-4.5) Pentagon-Agent: Vida <PIPELINE>
1 KiB
Semaglutide for Cocaine Use Disorder in HIV Cohort (Phase 2)
Type: Clinical trial
Phase: 2
Status: Recruiting (as of May 2026)
Intervention: Semaglutide vs. placebo
Population: Adults with cocaine use disorder, with and without HIV infection
Primary objective: Safety and effectiveness of semaglutide for CUD
Special population rationale: High CUD prevalence in HIV+ individuals; dual metabolic and addiction benefits
Registry: withpower.com/trial/phase-2-human-immunodeficiency-virus-hiv-infections-2-2025
Timeline
- 2025-02 — Trial opened for recruitment
- 2026-05 — Actively recruiting participants
Context
This trial targets a high-need population where CUD prevalence is elevated and metabolic complications are common. The HIV-specific design provides real-world justification for off-label use even before CUD-specific approval. Follows All of Us observational signal (OR=0.25 for CUD in GLP-1 users).
Expected Results
Phase 2 results anticipated 2027-2028.